Zum Hauptinhalt springen Zur Suche springen Zur Hauptnavigation springen
Herzlich Willkommen!
This highly informative and clearly written book presents the basic science and the latest data on hereditary breast and ovarian cancer (HBOC) to provide an up-to-date and holistic overview of the disease. It starts off by presenting the molecular mechanisms, genetic testing and counseling, and variants of unknown significance (VUS) to help readers understand the contemporary interpretation of the disease. Further chapters focus on the surveillance, diagnosis and treatment, including chemoprevention, risk reduction and drug development based on molecular mechanisms. It also includes a chapter on the latest findings from the HBOC database, ethical issues and the parp inhibitors, and discusses innovative thinking to manage and understand the disease. Hereditary Breast and Ovarian Cancer - Molecular Mechanism and Clinical Practice offers breast surgeons, medical oncologists, gynecological oncologists and genetic counselors a comprehensive overview of the disease. Providing insights into recent scientific findings and further avenues for investigation, it is also a thought-provoking and informative read for researchers and scholars.
ISBN: 9789811645204
Sprache: Englisch
Seitenzahl: 324
Produktart: Gebunden
Herausgeber: Aoki, Daisuke Miki, Yoshio Nakamura, Seigo
Verlag: Springer Singapore
Veröffentlicht: 21.10.2021
Untertitel: Molecular Mechanism and Clinical Practice
Schlagworte: Breast Cancer Chemoprevention Genetic Testing Gynecological Oncology HBOC Hereditary Breast and Ovary Cancer Oncology Ovarian Cancer Precision Medicine Risk Reduction
Seigo Nakamura Department of Breast Surgical OncologyShowa University, School of MedicineTokyo, Japan Daisuke AokiDepartment of Obstetrics and Gynecology,Keio University School of Medicine,Tokyo, Japan   Yoshio MikiDepartment of Molecular Genetics, Medical Research Institute,Tokyo Medical and Dental University,Tokyo, Japan

Das könnte Sie auch interessieren

Verwandte Artikel

Hereditary Breast and Ovarian Cancer

117,70 CHF*